ro 11-2933 has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bicknell, SR; Hamilton, T; Kaye, SB; Morrison, JG; Plumb, JA; Setanoians, A; Wishart, GC | 1 |
| Mazzoni, A | 1 |
2 other study(ies) available for ro 11-2933 and Ovarian Neoplasms
| Article | Year |
|---|---|
Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Topics: Animals; Calcium Channel Blockers; Doxorubicin; Drug Resistance; Drug Synergism; Epirubicin; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Propylamines; Quinidine; Tumor Cells, Cultured; Verapamil | 1994 |
In vitro reversal of doxorubicin resistance by the tiapamil analog RO 11-2933 in human ovarian cancer cells.
Topics: Doxorubicin; Drug Resistance; Drug Synergism; Female; Humans; Ovarian Neoplasms; Propylamines; Tumor Cells, Cultured | 1990 |